Recombinant AAV-CRB2 Vector for Retinal Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective for Leber's congenital amaurosis type 8 (LCA8) and retinitis pigmentosa 12 (RP12) caused by mutations in the CRB1 gene, leading to severe visual impairment and blindness, with no available therapeutics to prevent, delay, or treat these retinal disorders without significant toxicity.
Innovation Solution
A gene therapy vector comprising a nucleotide sequence encoding a Crumbs homologue-2 (CRB2) protein, specifically using a recombinant adeno-associated virus (rAAV) vector to express a biologically-functional CRB2 protein in the retina, targeting Müller glia cells and photoreceptors to restore retinal function and structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is applied to treat LCA8 and RP12 caused by CRB1 mutations, then retinal function and structure can be restored, but the complexity of the treatment increases due to the need for viral vectors and genetic manipulation
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver the CRB2 gene to retinal cells. The AAV vector acts as a mediator that safely transports the therapeutic gene across the blood-retina barrier and into target cells, resolving the contradiction by providing a reliable delivery mechanism while managing the complexity through standardized viral vector technology
Solution Approach 2:
The patent introduces a functional copy of the CRB2 gene to compensate for the defective CRB1 gene. By delivering a working copy of a related gene (CRB2) that can perform similar functions, the therapy restores retinal function without requiring direct correction of the complex mutated CRB1 gene, thus improving reliability while managing genetic manipulation complexity
2Reliability
If current treatments are used for CRB1 mutation-related retinal disorders, then treatment simplicity is maintained, but treatment effectiveness is insufficient leading to severe visual impairment and blindness
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach from conventional pharmacological or surgical methods to gene-based therapy. By transitioning to genetic-level intervention using AAV vectors, the treatment achieves superior effectiveness in restoring retinal function, accepting increased complexity as necessary for the breakthrough in therapeutic capability
3Reliability
If CRB2 protein is expressed in Müller glia cells and photoreceptors, then retinal structure and function are preserved, but the risk of immune response and toxicity increases
Solution Approach 1:
The patent employs tissue-specific promoters to drive CRB2 expression specifically in Müller glia cells and photoreceptors, rather than ubiquitous expression. This localized expression strategy ensures therapeutic benefit to the affected cells while minimizing exposure to other tissues, thereby reducing the risk of systemic immune responses and off-target toxicity
Solution Approach 2:
The patent uses self-inactivating AAV vector designs that limit long-term persistence of the viral genome and reduce the risk of insertional mutagenesis. By designing the vector to be transient and self-limiting, the therapy achieves its therapeutic effect while minimizing long-term harmful effects such as chronic immune activation or carcinogenicity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates toa Crumbs homologue (CRB) therapeutic for use as a medicament or in a method of treatment or prophylaxis, for example in the treatment or prophylaxis of a retinal disorder due to mutations in the Crumbs homologue-1 (CRB1)gene, such as Leber's congenital amaurosis 8(LCA8) or retinitis pigmentosa 12 (RP12).In particular, the present invention relates to a recombinant viral vector comprising CRB2 or modified non-toxic forms of either CRB1or CRB3 that resemble CRB2.